Two Health Care Stocks at Risk of Significant Decline This August
Health Care Stocks Warning: As of August 20, 2025, two health care stocks, Tarsus Pharmaceuticals and Premier Inc, are showing overbought signals based on their RSI values, indicating potential caution for momentum-focused investors.
Tarsus Pharmaceuticals Performance: Tarsus reported strong quarterly results with over $100 million in net sales, leading to a stock price increase of approximately 27% over the past month, despite a slight drop of 1.7% recently.
Premier Inc Financial Results: Premier Inc announced better-than-expected fourth-quarter results, resulting in a 25% stock price increase over the last month, with shares closing at $26.21 after a gain of 7.3%.
RSI Indicators: Tarsus has an RSI value of 76.2, while Premier's is significantly higher at 86.9, suggesting both stocks may be overbought and warrant investor attention.
Trade with 70% Backtested Accuracy
Analyst Views on TARS
About TARS
About the author
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Biotech Sector Performance: The biotech sector is experiencing significant stock surges and advancements in trials and regulatory filings, highlighting the importance of distinguishing between short-term price fluctuations and long-term value for investors.
Notable Stock Highlights: Several biotech companies, including Olema Pharmaceuticals, Owlet Inc., and Rigel Pharmaceuticals, have reached new 52-week highs, driven by positive trial results and strategic offerings.
Upcoming Developments: Companies like Jazz Pharmaceuticals and Tarsus Pharmaceuticals are preparing for important regulatory submissions and clinical trials, indicating ongoing innovation and potential market impact.
Financial Outlooks: Firms such as Natera and Kiniksa Pharmaceuticals have provided updated revenue guidance for 2025, reflecting growth expectations and strategic advancements in their respective fields.
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Quarterly Performance: Tarsus Pharmaceuticals reported a quarterly loss of $0.30 per share, better than the expected loss of $0.35, and significantly improved from a loss of $0.61 per share a year ago, marking a 14.29% earnings surprise.
Revenue Growth: The company achieved revenues of $118.7 million for the quarter, exceeding the Zacks Consensus Estimate by 2.80% and showing substantial growth from $48.12 million in the same quarter last year.
Stock Outlook: Tarsus Pharmaceuticals has seen a 26% increase in its stock price since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Tarsus operates, ranks in the top 39% of Zacks industries, indicating a favorable outlook, while Codexis, another company in the same sector, is set to report its quarterly results soon.
